The endothelium plays a key role in the control of vascular tone and alteration in endothelial cell function contributes to several cardiovascular disease states. Endothelium-dependent dilation is mediated by NO, prostacyclin, and an endothelium-derived hyperpolarizing factor (EDHF). EDHF signaling is thought to be initiated by activation of endothelial Ca 2ϩ -activated K ϩ channels (K Ca ), leading to hyperpolarization of the endothelium and subsequently to hyperpolarization and relaxation of vascular smooth muscle. In the present study, we tested the functional role of the endothelial intermediateconductance K Ca (IK Ca /K Ca 3.1) in endothelial hyperpolarization, in EDHF-mediated dilation, and in the control of arterial pressure by targeted deletion of K Ca 3.1. K Ca 3.1-deficient mice (K Ca 3.1 Ϫ/Ϫ ) were generated by conventional gene-targeting strategies. Endothelial K Ca currents and EDHF-mediated dilations were characterized by patch-clamp analysis, myography and intravital microscopy. Disruption of the K Ca 3.1 gene abolished endothelial K Ca 3.1 currents and significantly diminished overall current through K Ca channels. As a consequence, endothelial and smooth muscle hyperpolarization in response to acetylcholine was reduced in K Ca 3.1 Ϫ/Ϫ mice. Acetylcholine-induced dilations were impaired in the carotid artery and in resistance vessels because of a substantial reduction of EDHF-mediated dilation in K Ca 3.1 Ϫ/Ϫ mice. Moreover, the loss of K Ca 3.1 led to a significant increase in arterial blood pressure and to mild left ventricular hypertrophy. These results indicate that the endothelial K Ca 3.1 is a fundamental determinant of endothelial hyperpolarization and EDHF signaling and, thereby, a crucial determinant in the control of vascular tone and overall circulatory regulation. (Circ Res. 2006;99:537-544.) 
T he vascular endothelium plays a key role in the control of organ perfusion and contributes to the regulation of arterial blood pressure by releasing vasoactive factors that modulate the contractile state of the underlying smooth muscle. 1 In response to classical agonists, such as acetylcholine (ACh) and bradykinin, as well as to hemodynamic stimuli, 2 the endothelium produces, in principle, 3 vasodilating factors, nitric oxide (NO), 1,3 prostacyclin (PGI 2 ), 4 and an endothelium-derived hyperpolarizing factor (EDHF). 5 Although the modes of action of NO and PGI 2 became clear 20 years ago, the nature of the latest identified factor, EDHF, is still controversial and debated thoroughly since its discovery in the late eighties. 5, 6 Regarding the relative contribution of NO and EDHF within the vascular tree, it appears that EDHF becomes more important when vessel diameter decreases, whereas NO seems to be predominant in large arteries. 7 Importantly, defects in the NO system and also in EDHF signaling, as demonstrated more recently, are pathologically relevant in disease states such as hypertension, 8, 9 diabetes, 10 and renal insufficiency. 11 Studies in transgenic mice deficient in either endothelial NO synthase (eNOS) 12 or the PGI 2 -generating cyclooxygenase-1 (COX-1), 13, 14 or in both enzymes, 14 revealed that endothelium-dependent dilation is still preserved, which was attributed to a compensatory effect by the respective other dilator and supposedly by EDHF.
Despite considerable progress in recent years, the identity of EDHF and the cellular mechanisms underlying EDHF signaling upstream of smooth muscle hyperpolarization and relaxation remains elusive. Several chemical factors among them, K ϩ ions and cytochrome P450-generated metabolites of arachidonic acid, have been suggested to serve as EDHF or contribute to EDHF signaling by intraendothelial mechanisms. 5, 6, 15 In addition, a nonchemical mechanism characterized by the direct spread of hyperpolarization from the endothelium to the subjacent smooth muscle via myoendothelial gap junctions was proposed to transfer the hyperpolarization directly, without the requirement for a factor, and account for the EDHF-related vasodilator principle. 6 In fact, in most vessels in different species including humans, the membrane hyperpolarization that occurs initially in the endothelium seems to be a prerequisite for the initiation of the EDHF signal. 5, 16 This endothelial hyperpolarization is in many tissues because of the activation of small-conductance Ca 2ϩ -activated K ϩ channels (K Ca 2.3, according to the new International Union of Basic and Clinical Pharmacology nomenclature; also known as SK Ca 3, KCNN3, SK3) and of intermediate-conductance Ca 2ϩ -activated K ϩ channels (K Ca 3.1; also known as IK1, KCNN4, IKCa1). 5,16 -27 These 2 K Ca channels are commonly known as endothelial IK Ca and SK Ca . As the combined and specific blockade of these channels abrogates endothelial hyperpolarization and the EDHF-type response, their activation is considered a hallmark herein. 5, 16, 17, 21, 23, 26, 28 However, in most studies, a combined blockade of K Ca 3.1 channels and of K Ca 2.3 was performed to study EDHF-type responses. Interestingly, in the human mesenteric endothelium, K Ca 3.1 seems to be of special importance because endothelial hyperpolarization is almost completely blocked by inhibitors of this channel, 29 suggesting that the 2 K Ca channels have specific functions, at least in certain vascular beds. However, the exact role of K Ca 3.1 as opposed to K Ca 2.3 to mediate endothelial hyperpolarization and its contribution to the control of vascular tone, EDHF signaling, and, possibly, the regulation of arterial pressure remain unclear.
To dissect the relative roles of K Ca 3.1 and K Ca 2.3, we generated mice with a targeted disruption of the K Ca 3.1 Ϫ/Ϫ gene. Here, we show that deletion of the K Ca 3.1 Ϫ/Ϫ gene and thus loss of K Ca 3.1 functions results in an impaired EDHFmediated dilation and elevated systemic blood pressure.
Materials and Methods
Detailed methods for generation of K Ca 3.1 Ϫ/Ϫ mice, 30 Southern blot analysis, routine genotyping, RT-PCR, Western blot analysis, patchclamp electrophysiology, 23, 29, 31 membrane-potential measurements, pressure myography, 23 intravital microscopy, 32 and tail-cuff and telemetric blood pressure measurements 33 are included in the online data supplement, available at http://circres.ahajournals.org.
Statistics
Data are given as meanϮSE or SEM as indicated. The Student's t test was used to assess differences between groups. Probability values of PϽ0.05 were considered significant.
Results

Generation of K Ca 3.1 ؊/؊ Mice
Mice deficient in K Ca 3.1 Ϫ/Ϫ were generated by homologous recombination in embryonic stem cells using conventional techniques ( Figure 1A ). This strategy deleted exon 4 of the K Ca 3.1 gene, which encodes the channel pore. Successful gene targeting of K Ca 3.1 was verified by Southern blot and PCR analysis ( Figure 1B and 1C). Loss of K Ca 3.1 gene expression in K Ca 3.1 Ϫ/Ϫ was confirmed by RT-PCR in total mRNA extracts from spleen ( Figure 1D ). The lack of the protein was proven by Western blot analysis ( Figure 1E ) of erythrocyte ghost membranes known to contain the K Ca 3.1 protein (also referred to as "Gardos" channel).
Heterozygous K Ca 3.1 Ϫ/ϩ breeding pairs produced offspring in a Mendelian manner: 25% were homozygous wild-type (ϩ/ϩ), 52% heterozygous (Ϫ/ϩ), and 23% homozygous K Ca 3.1 Ϫ/Ϫ . Homozygous K Ca 3.1 Ϫ/Ϫ were viable and fertile. Mating of K Ca 3.1 Ϫ/Ϫ males with K Ca 3.1 Ϫ/Ϫ females produced normal offspring and litter sizes, similar to a different K Ca 3.1 Ϫ/Ϫ strain. 34
Deficiency of Endothelial K Ca 3.1 and Diminished Endothelial Hyperpolarization in K Ca 3.1 ؊/؊ Mice
To evaluate whether the K Ca 3.1 gene deletion results in diminished functional K Ca currents in the endothelium of K Ca 3.1 Ϫ/Ϫ mice, we performed whole-cell patch-clamp experiments in freshly isolated aortic endothelial cells (AEC) of K Ca 3.1 Ϫ/Ϫ (nϭ8) and K Ca 3.1 ϩ/ϩ mice (nϭ7) and in carotid artery endothelial cells (CAEC) in situ of these mice (nϭ3 each). For the activation of K Ca channels, cells were dialyzed with a pipette solution containing 3 mol/L Ca 2ϩ . To verify the lack of K Ca 3.1 currents, whole-cell patch-clamp experiments were conducted first in the presence of the K Ca 2.3 blocker UCL1684 (100 nmol/L) 35 to unmask K Ca 3.1 currents from K Ca 2.3 currents in AEC and CAEC in situ. K Ca 3.1 currents were not detectable in AEC and CAEC of K Ca 3.1 Ϫ/Ϫ mice, whereas K Ca 3.1 currents were present in AEC and in CAEC of K Ca 3.1 ϩ/ϩ littermates. Original current traces and mean K Ca current standardized to cell capacitance are shown in Figure 2A and 2B. TRAM-34, a selective blocker of K Ca 3.1 channels, 36 completely blocked this current (nϭ10; Figure 2 ), demonstrating that the UCL1684-insensitive current is indeed mediated by K Ca 3.1. Moreover, this indicates that K Ca 3.1 together with K Ca 2.3 confers the K Ca currents in wild-type AEC, 24, 37 as in rat EC, as shown previously. 21 In a second set of experiments, we determined mixed K Ca 3.1/K Ca 2.3-current densities in AEC and in CAEC in situ of K Ca 3.1 ϩ/ϩ mice and K Ca 2.3-current densities in AEC and in CAEC in situ of K Ca 3.1 Ϫ/Ϫ mice. Compared with the composite K Ca 3.1/K Ca 2.3current density in EC of wild-type mice, the K Ca 2.3-current density in K Ca 3.1 Ϫ/Ϫ mice was significantly smaller ( Figure  2B ). K Ca 2.3-current densities (determined in the presence of TRAM-34) were similar in AEC of both genotypes (K Ca 3.1 Ϫ/Ϫ : 14Ϯ2 pA/pF, nϭ5; wild type: 10Ϯ3 pA/pF, nϭ13). Also, cell capacitance was not different between genotypes in AEC (K Ca 3.1 Ϫ/Ϫ : 9Ϯ1; wild type: 8Ϯ1 pF; nϭ21 and 25, respectively) and in CAEC in situ (K Ca 3.1 Ϫ/Ϫ : 8Ϯ1; wild type: 9Ϯ1 pF; nϭ8 and 12, respectively). These results indicate that deletion of K Ca 3.1 gene reduced the overall endothelial K Ca -current density by Ϸ50%.
To test whether the loss of endothelial K Ca 3.1 currents and the reduced overall K Ca currents in K Ca 3.1 Ϫ/Ϫ mice led to an impaired agonist-induced endothelial hyperpolarization, we conducted membrane-potential measurements in AEC clusters (Ͼ20 cells) and in the endothelium of carotid artery in situ (CAE). Capacitance values of Ͼ150 pF indicated intact electrical coupling in AEC clusters and in EC of the carotid artery (CA) of K Ca 3.1 Ϫ/Ϫ and K Ca 3.1 ϩ/ϩ mice. As shown in Figure 3 , the amplitude of the hyperpolarization in response to ACh (100 nmol/L) was significantly smaller in both preparations studied in K Ca 3.1 Ϫ/Ϫ (at 100 nmol/L ACh: Ϸ⌬Ϫ10 mV versus Ϸ⌬Ϫ25 mV in wild type). Moreover, the ACh-induced hyperpolarization was completely reversed by the K Ca 2.3 blocker UCL1684 (100 nmol/L) in K Ca 3.1deficient tissues, whereas in wild-type tissues, a combination of UCL1684 and TRAM-34 (1 mol/L) was required to fully reverse the hyperpolarization response. Similarly, membrane hyperpolarization in response to the K Ca 3.1/K Ca 2.3 opener DC-EBIO (10 mol/L) 38 was significantly reduced in AEC clusters obtained from K Ca 3.1 Ϫ/Ϫ mice (Figure 3 ). Nevertheless, the endothelial resting potential did not differ between the genotypes ( Figure 3B ) and was likewise not altered in the presence of 1 or both K Ca blockers, indicating that K Ca 3.1 and K Ca 2.3 do not contribute considerably to the setting of the resting potential under these conditions in these cells.
Membrane potential measurements in smooth muscle of CAs as performed by using conventional sharp electrode technique (from the adventitial side) revealed that smooth muscle hyperpolarization to ACh (100 nmol/L) was blunted in CAs (nϭ6) of K Ca 
Resting potentials were similar (Ϫ39Ϯ2 mV in K Ca 3.1 Ϫ/Ϫ versus Ϫ43Ϯ2 mV in wild-type mice; PϭNS).
Together, these results suggest that the loss of endothelial K Ca 3.1 leads to an impaired endothelial and smooth muscle hyperpolarization in response to agonists.
Impaired EDHF-Mediated Dilation in K Ca 3.1 ؊/؊ Mice
To test whether the lower K Ca -current densities and the reduced endothelial hyperpolarization response in K Ca 3.1 Ϫ/Ϫ led to impaired endothelial function and especially a defective EDHF-mediated dilation, we determined ACh-and DC-EBIO-induced dilator responses in CAs of K Ca 3.1 Ϫ/Ϫ and wild-type mice. In the presence of the NO synthase blocker N G -nitro-L-arginine (L-NNA) (100 mol/L) and the COX inhibitor INDO (10 mol/L), ACh-induced dilations were significantly reduced in K Ca 3.1 Ϫ/Ϫ mice. Original traces and concentration-response curves are shown in Figure 4A . At 100 nmol/L ACh, the dilation of CAs of K Ca 3.1 Ϫ/Ϫ mice was approximately half of the dilatory response observed in wild-type mice. The EDHF-type dilation was partially suppressed by UCL1684 (100 nmol/L) and completely abrogated by the combination of UCL1684 and TRAM-34 (1 mol/L) in wild-type mice. In contrast, UCL1684 was sufficient to effectively block EDHF-type dilations in K Ca 3.1 Ϫ/Ϫ mice, and TRAM-34 had no further inhibitory effects ( Figure 4A , lower right). Notably, UCL1684 alone or in combination with TRAM-34 did not reduce vessel diameter in wild-type or K Ca 3.1 Ϫ/Ϫ mice, suggesting that these channels do not initiate or exert a tonic endothelial dilator effect in this preparation.
In the absence of blockers of NOS and COX, endotheliumdependent dilation was larger overall in wild-type and K Ca 3.1 Ϫ/Ϫ mice. This is in line with the notion that, particularly, NO synthesis and release contribute significantly to ACh-induced dilation in this artery ( Figure 4B ). Prostacyclin did not contribute to this enhanced dilator response in wild-type and K Ca 3.1 Ϫ/Ϫ mice because INDO alone had no inhibitory effect (also see Figure I in the online data supplement).
However, when compared with wild-type mice, the overall larger ("total") ACh-induced dilation was still reduced in K Ca 3.1 Ϫ/Ϫ mice ( Figure 4B ). Because inhibition of NOS reduced ACh-induced dilation to a similar extent in wild-type and in K Ca 3.1 Ϫ/Ϫ mice, it seems that the reduction of the total endothelium-dependent dilation in K Ca 3.1 Ϫ/Ϫ mice reflects an impaired EDHF-type response in these mice. Moreover, the persisting impairment of the ACh-induced dilation in K Ca 3.1 Ϫ/Ϫ mice in the presence of intact NO synthesis indicates that the diminished EDHF-type dilation is not compensated by an enhanced NO or prostacyclin release. Dilation in response to direct pharmacological activation of both endothelial K Ca by the potent K Ca 3.1/K Ca 2.3 opener DC-EBIO (10 mol/L) was also significantly diminished in CAs of K Ca 3.1 Ϫ/Ϫ mice ( Figure 4C ), which shows that the loss of K Ca 3.1 also blunts pharmacologically induced EDHF-type dilation.
Vasoconstriction of CAs in response to phenylephrine (PE) (1 mol/L) did not differ between K Ca 3.1 Ϫ/Ϫ mice and wild-type littermates. PE contracted CAs of K Ca 3.1 ϩ/ϩ mice by 114Ϯ8 m (from 572Ϯ9 to 458Ϯ10 m; nϭ20) and CAs of K Ca 3.1 Ϫ/Ϫ mice by 125Ϯ9 m (from 568Ϯ8 to 448Ϯ10 m; nϭ23). Endothelium-independent dilation in response to sodium nitroprusside (SNP) (1 mol/L) was also unchanged in K Ca 3.1 Ϫ/Ϫ mice. SNP dilated PE-precontracted CAs of K Ca 3.1 ϩ/ϩ mice by 106Ϯ8 m and CAs of K Ca 3.1 Ϫ/Ϫ mice by 119Ϯ10 m (PϭNS). Likewise, pressure-induced vasoconstriction (myogenic tone), as determined in myogenically active small arteries (gracilis artery, Ϸ100 m in diameter), was not altered in K Ca 3.1 Ϫ/Ϫ mice (data not shown). These results indicate that deficiency of K Ca 3.1 does not alter the tonic dilatory effect of the endothelium on myogenic tone or tone initiated by ␣ 1 -adrenergic receptor stimulation using PE. In this regard, it is noteworthy that K Ca 2.3 have been proposed to a play role herein 24 (for additional discussion, see the online data supplement).
Collectively, these data from pressure myograph experiments show that the lack of K Ca 3.1 impairs ACh-induced dilation predominantly by affecting the EDHF-type dilation.
In addition, the contribution of K Ca 3.1 to endotheliumdependent dilations was investigated in resistance-sized vessels in the cremaster microcirculation in the presence of inhibitors of NOS and COX. The maximal diameter of the arterioles investigated ranged from 16 to 75 m and was similar in wild-type and K Ca 3.1 Ϫ/Ϫ mice (36Ϯ1 versus 38Ϯ1 m, respectively; nϭ80 arterioles in 8 mice, each genotype). The arteriolar dilation in response to ACh was significantly reduced in K Ca 3.1 Ϫ/Ϫ mice, which was most pronounced at intermediate concentrations ( Figure  5 ). In contrast, the dilation in response to SNP (10 mol/L) was similar in both genotypes (wild-type: 63Ϯ3%; K Ca 3.1 Ϫ/Ϫ : 66Ϯ3% of maximum dilation; PϭNS). Thus, the K Ca 3.1 channel is also required in arterioles for an intact EDHF-type dilation.
Elevated Blood Pressure in K Ca 3.1 ؊/؊ Mice
Because deficiency in K Ca 3.1 Ϫ/Ϫ resulted in reduced K Cacurrent density, decreased hyperpolarization responses, and an impaired EDHF-type dilation in conducting and resistance vessels, we questioned whether this has functional consequences on the overall circulation. We tested this hypothesis by measuring systolic blood pressure (SBP) and diastolic blood pressure (DBP) using tail-cuff plethysmography. Compared with wild-type littermates, SBP and DBP were significantly increased by Ϸ13 mm Hg and Ϸ12 mm Hg in K Ca 3.1 Ϫ/Ϫ mice, respectively. The calculated mean arterial pressure was increased by Ϸ14 mm Hg (Table) . In smaller sets of animals (nϭ4, per group), we conducted 24-hour pressure measurements by telemetry which revealed a comparable increase of the mean pressure in K Ca 3.1 Ϫ/Ϫ mice (115Ϯ2 versus 108Ϯ1 mm Hg; PϽ0.05) and confirmed the tail-cuff measurements. However, heart rate was unchanged (K Ca 3.1 Ϫ/Ϫ : 637Ϯ22; wild-type: 633Ϯ17 bpm). Interestingly, we also found a slight increase in heart weight and a larger cross-sectional area of the left ventricle on histological examination in K Ca 3.1 Ϫ/Ϫ (Table) . This might be indicative of mild left-ventricular hypertrophy, presumably resulting from increased blood pressure because the cross-sectional area of the right ventricle was not altered in K Ca 3.1 Ϫ/Ϫ mice.
Discussion
In the present study, we show that the targeted disruption of the K Ca 3.1 gene abolished K Ca 3.1 functions and greatly reduced endothelial K Ca currents. This reduction of K Ca currents was associated with an impaired endothelial hyperpolarization and EDHF-type dilation in conducting and resistance vessels in response to the classical endothelial agonist ACh. In addition, systemic blood pressure was elevated in K Ca 3.1 Ϫ/Ϫ mice. Thus, by using a conventional gene-targeting approach, we demonstrate that the K Ca 3.1, on its own, is an important determinant of the capability of the endothelium to hyperpolarize on stimulation and, thereby, apparently supports EDHF-type dilation. Moreover, we show for the first time that targeted disruption of a crucial endothelial component of the EDHF-signaling pathway, ie, K Ca 3.1, has an impact on systemic blood pressure regulation.
In response to agonist stimulation, endothelial hyperpolarization is considered to be a prerequisite for the initiation of the EDHF-signaling pathway. 5 The endothelial K Ca channels mediating this initial endothelial hyperpolarization were identified by electrophysiologic, pharmacological, and molecular approaches as K Ca 3.1 and K Ca 2.3 channels in arteries from mice, 24 rats, 21,23 pigs, 22 and humans. 29 These 2 K Ca channels are not expressed in mature contractile vascular smooth muscle cells of CAs of mice (also see supplemental Figure II ) and of rats. 23, 39 In mice as in rats, endothelial K Ca 3.1 and K Ca 2.3 seem to contribute almost equally to the composite endothelial K Ca currents, whereas in human EC in intact mesenteric artery preparations, endothelial K Ca currents and hyperpolarization are largely mediated by K Ca 3.1. 29 In the present study, we found that deficiency of K Ca 3.1 caused a reduction of K Ca currents in AEC and CAEC in response to ACh and a pharmacological activator of K Ca . The amplitude of the residual K Ca current in K Ca 3.1 Ϫ/Ϫ mice, which was mediated by K Ca 2.3, was approximately half of the amplitude of the composite K Ca 3.1/K Ca 2.3 current observed in wild-type mice, which suggests that K Ca 3.1 and K Ca 2.3 channels contribute equally to endothelial hyperpolarization. Moreover, the current in K Ca 3.1 Ϫ/Ϫ mice had roughly the same amplitude as the hyperpolarizing current in wild-type EC after pharmacological inhibition of K Ca 3.1. This important finding suggests that the lack of K Ca 3.1 is not compensated for by a higher activity and/or expression level of the K Ca 2.3.
The functional expression of both channels in the same cell implies that they have different functions or that their combined activation is needed to generate a complete hyperpolarization after endothelial stimulation. This latter could be attributable to a necessity to counteract concomitant depolarizing currents through second-messenger-gated cation chan- nels of the transient receptor potential family after stimulation of G protein-coupled receptors. 26, 28, 40 Assuming a tight electrical coupling of the endothelium and smooth muscle via myoendothelial gap junctions, 6 the endothelium may also be subjected to a depolarizing effect of the smooth muscle. In any case, the present study revealed that the loss of K Ca 3.1 dampened the endothelial hyperpolarization response to ACh as well as to the potent K Ca 3.1/K Ca 2.3 opener DC-EBIO. This highlights the requirement of this channel, which adds to endothelial hyperpolarization on stimulation to achieve its full amplitude. Whether the K Ca 3.1 is simply another source of hyperpolarizing current or acts as an amplifier cannot be clearly decided by the present study. However, it should be noted that Ϸ50% of the amplitude of the hyperpolarization response, which is mediated by K Ca 2.3 was preserved.
Cardiovascular Parameters in
Because the endothelial hyperpolarization is critical to induce EDHF-type dilation and may be important for NOmediated dilation as well, we assessed endotheliumdependent responses in arteries of K Ca 3.1-deficient mice. In the carotid artery of wild-type mice, NO mediated nearly half of the dilation at intermediate concentrations of ACh (100 nmol/L). Because prostacyclin does not contribute in these vessels, which was verified by the lack of effect of the COX inhibitor INDO, the other half of the response was NO-and prostacyclin-independent and thus apparently attributable to an EDHF-type dilation. This large contribution of EDHF to endothelium-dependent dilation in this artery differs from earlier findings of a lower, or even no, contribution of EDHF in carotid arteries of rats (Ϸ20% EDHF) 11, 23 and mice, 41 respectively. Likely explanations for this discrepancy are the use of different experimental approaches (pressure [this study] versus wire myography) or different compounds and concentrations used for precontraction such as phenylephrine (this study), prostaglandins, or thromboxane A 2 mimetics, ie, U46619. Especially the latter was shown to interfere with EDHF signaling in a negative fashion. 25 However, the loss of K Ca 3.1 reduced the overall endothelium-dependent dilation in the carotid artery. This reduction was not caused by an attenuation of the NO-mediated part of the response because inhibition of NO synthase was equally effective in both genotypes. This suggests an alteration of the EDHF-type dilation, as verified after blockade of NO and prostaglandin synthesis. Importantly, EDHF cannot be compensated for by NO and/or prostaglandins because the overall endotheliumdependent dilation is blunted. Although it is widely accepted that endothelial hyperpolarization mediated by K Ca 3.1 or K Ca 2.3 is required for generating an EDHF-mediated dilation, the specific contribution of either K Ca 3.1 or K Ca 2.3 is still unclear. Depending on vessel type, species, and experimental approach, a single blocker or only the combination of both blockers is effective in suppressing endothelial hyperpolarization, smooth muscle hyperpolarization, and EDHFmediated dilation. 23, 26, 28, 42 In the present study on carotid artery of wild-type mice, blockade of both K Ca 3.1 and K Ca 2.3 was required to suppress EDHF-type dilation, which is reflected also by the complete inhibition of endothelial hyperpolarization, and thus both endothelial K Ca channels are important in initializing a full EDHF dilation.
This hypothesis was further verified by the gene-targeting approach in this present study, as K Ca 3.1 Ϫ/Ϫ mice exhibit an impaired EDHF-mediated dilation in the CA, which is most likely attributable to the reduced capability of the endothelium to hyperpolarize. The important role of K Ca 3.1 is not restricted to conducting arteries. Also, in resistance vessels of the microcirculation, K Ca 3.1 is critical to initiate a full EDHF-type dilation and its role appears to be prominent at lower concentrations of ACh. Because NO and prostaglandins do not contribute substantially to dilator responses in this preparation, 32, 43 we have not assessed the role of NO in this study. However, a considerable portion of the EDHFmediated dilation was preserved in both vessel types. This remaining dilation relied on the activation of K Ca 2.3 because the inhibitor of K Ca 2.3 almost completely blocked the EDHFtype dilation in K Ca 3.1-deficient mice.
The physiological importance of the impaired endothelial hyperpolarizing capability and diminished EDHF-mediated dilation in K Ca 3.1 Ϫ/Ϫ mice is reflected by the considerable increase in arterial pressure. This may reflect the importance of endothelial hyperpolarizations to coordinate vascular behavior along the vessel wall through gap junctions. 32, 44 It is noteworthy, that a similar association of impaired endothelial K Ca 3.1 (and K Ca 2.3) expression and diminished EDHFmediated dilation is present in uremic rats 11 and in restenosis disease, 21 which supports the notion that a loss of endothelial K Ca 3.1 is relevant in cardiovascular diseases. With respect to the K Ca 2.3 channel, a recent study using transgenic K Ca 2.3 mice showed that suppression of K Ca 2.3 expression increased myogenic and phenylephrine-induced tone and systemic blood pressure, thus highlighting the functional role of this channel in endothelial control of vascular tone (for additional discussion, please see the online data supplement).
In conclusion, the present study demonstrated that the endothelial K Ca 3.1 contributes considerably to endothelial hyperpolarization and EDHF-mediated dilations. Importantly, the loss of K Ca 3.1 cannot be compensated for by enhanced activity of K Ca 2.3 and/or NO and, therefore, has an impact on overall circulatory function as reflected by the elevation of systemic blood pressure. Thus, this study presents first evidence that genetic deletion of one major component of the EDHF-signaling pathway significantly impairs cardiovascular functions. Conversely, selective openers of endothelial K Ca 3.1 may provide a novel therapeutic approach for the treatment of vascular diseases characterized by endothelial dysfunction and hypertension. 
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